Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

NCT04018833 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Macular Edema
Diabetic Retinopathy

Interventions

DRUG: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
DRUG: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]

Sponsor

Bernardete Pessoa MD